PRESS RELEASE published on 11/13/2025 at 17:57, 9 months 27 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils GENSIGHT BIOLOGICS SA Heights Capital Management CVI Investments Inc.
BRIEF published on 10/30/2025 at 07:35, 10 months 11 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 10/30/2025 at 07:35, 10 months 11 days ago GenSight Biologics : Feu vert pour un traitement compassionnel aux États-Unis FDA GenSight Biologics NOHL Accès Compassionnel GS010/LUMEVOQ®
PRESS RELEASE published on 10/30/2025 at 07:30, 10 months 11 days ago Informations privilégiées / Autres communiqués GenSight Biologics a obtenu les autorisations réglementaires pour un traitement compassionnel aux États-Unis avec GS010/LUMEVOQ, visant la Neuropathie Optique Héréditaire de Leber FDA GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ Traitement Compassionnel
BRIEF published on 09/29/2025 at 23:05, 11 months 11 days ago GenSight Biologics annonce ses résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie GenSight Biologics Programmes D'accès Précoce
BRIEF published on 09/29/2025 at 23:05, 11 months 11 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 11 months 11 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 23:00, 11 months 11 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie résultats financiers du premier semestre 2025 : gestion optimisée de trésorerie, financement post-clôture, transfert de fabrication, protocole d'étude soumis à l'ANSM Résultats Financiers Financement Trésorerie GenSight Biologics Étude ANSM
PRESS RELEASE published on 09/29/2025 at 21:48, 11 months 11 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 1 year ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
Published on 09/10/2026 at 22:25, 4 hours 48 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 11 hours 53 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 12 hours 13 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 12 hours 36 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 3 hours 8 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 3 hours 12 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 4 hours 33 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 5 hours 2 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 5 hours 6 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 7 hours 43 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 7 hours 43 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 9 hours 3 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 9 hours 28 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 9 hours 31 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
